Houston startups dominate ‘most-promising’ companies announcement at annual event

on the list

This year, seven of the 10 most-promising life science companies are based in Houston. Photo courtesy of Rice Alliance

Rice University played host this week to the 12th annual Texas Life Science Forum, where life science leaders and startup founders could network, learn and present pitches on their solutions to a wide array of health-related issues.

Hosted by Rice Alliance for Technology and Entrepreneurship and BioHouston on November 7, the event brought together more than 600 attendees for a series of keynote speakers and panels. This year, 45 early-stage therapeutic, diagnostic, medical device and digital health companies—many of which are based in Houston—also pitched their concepts.

Fort Worth-based AyuVis Research walked away from the event with the two top recognitions: The Michael E. DeBakey Memorial Life Science Award and the People's Choice Award. The company, which has developed a small molecule immunotherapy targeting bronchopulmonary dysplasia (BPD) in preterm neonates and other respiratory disorders. The company is raising a $20 million Series A round to support its clinical development and is slated to pitch at IGNITE Health’s Fire Pitch 2023 today, November 9, at the Ion.

Each year the Rice Alliance and BioHouston also name its 10 most promising life science companies, selected by investors—seven out of 10 of which are based in Houston. This year's selection included the following companies, in alphabetical order:

  • 7 Hills Pharma: This Houston-based clinical stage immunotherapy company has developed the concept of allosteric activation of integrins to facilitate cell adhesion and promote immune responses. The concept has uses in preventing infection and cancer, and increasing the effectiveness of oncology drugs and infectious disease vaccines.
  • Bairitone Health: This Houston-based company is building a scalable diagnostic system for sleep apnea anatomy utilizing home-use wearable, passive Sonar technology and AI techniques.
  • Diakonos Oncology: Also based in Houston, Diakonos' Dendritic Cell Vaccine was awarded the FDA’s Fast Track designation. The clinical-stage biotech company's immunotherapies have shown early successes for hard-to-reach, aggressive cancers like Glioblastoma Multiforme.
  • Mongoose Bio: With more than 20 years of research, Mongoose specializes in T cell-based therapies for diverse solid tumors TCR-based therapies in cancer patients. The Houston-based company has developed an immunopeptidome discovery platform for TCR-based therapies in cancer patients.
  • Nandi Life Sciences: Nandi is developing antibodies for Avastin-resistant ovarian cancer, with
  • further application in breast, colorectal and lung cancer. The company is based out of Texas Medical Center Innovation.
  • NKILT Therapeutics: This Houston-based company's seed-stage cell therapy has applications in solid tumors, such as colorectal cancer, ovarian cancer, clear cell renal carcinoma, endometrial
  • cancer and more. It is developing a novel and proprietary Chimeric ILT-Receptor.
  • NuVision Biotherapies: Based in the United Kingdom, NuVision has developed and proven a treatment for dry eye disease. It's known for its Omnigen and OmniLenz products and is raising a series A to scale, take the business to profitability and exit.
  • Panakeia Technologies: Also based in the UK, Panakeia has developed an AI-based software that can provide multi-omic biomarkers in minutes. Currently this process takes days or weeks. It's RuO platform can identify 4,500 known multi-omics cancer markers.
  • Taurus Vascular: A recent spin-out of the Texas Medical Center Innovation Biodesign program, Taurus is developing a novel, catheter-based solution for treating endoleaks, which can be related to aortic aneurysms.
  • YAP Therapeutics: The only California-based company to make the cut, this preclinical-stage biotech develops genetic medicines that leverage the company’s tissue renewal and regeneration platform to reverse and cure severe diseases, including heart failure, pulmonary diseases, retinal degeneration and hearing loss.

Last year, Bairitone Health took home the DeBakey and People's Choice awards.

From Your Site Articles
InformAI has three AI-based products geared at improving health care. Photo via Getty Images

Fresh off grant, Houston health tech company's AI aims to revolutionize diagnostics, care

data-driven

In Houston, we’re lucky to have top-tier doctors in the Texas Medical Center, ready to treat us with the newest technology. But what about our family members who have to rely on rural hospitals? Thanks to one Houston company, doctors in smaller community hospitals may soon have new tools at their disposal that could improve outcomes for patients around the world.

Since InnovationMap last caught up with Jim Havelka, CEO of InformAI, two years ago, that hope has come far closer to a reality. InformAI is a VC-backed digital health company. Part of JLABS @ TMC innovation facilities, the company uses artificial intelligence to develop both diagnostic tools and clinical outcome predictors. And two of the company’s products will undergo FDA regulatory testing this year.

SinusAI, which helps to detect sinus-related diseases in CT scans, received its CE Mark — the European equivalent of FDA approval — last year and is being sold across the Atlantic today, says Havelka. He adds that in the United States alone, there are roughly 700,000 sinus surgeries that the product is positioned to support.

Another product, RadOnc-AI, is designed to help doctors prescribe radiation dose plans for head and neck cancers.

“Ideally the perfect plan would be to provide radiation to the tumor and nothing around it,” says Havelka. “We’ve built a product, RadOnc-AI, which autogenerates the dose treatment plan based on medical images of that patient.”

It can be an hours-long process for doctors to figure out the path and dose of radiation themselves, but the new product “can build that initial pass in about five minutes,” Havelka says.

That in itself is an exciting development, but because this technology was developed using the expertise of some of the world’s top oncologists, “the first pass plan is in line with what [patients would] get at tier-one institutions,” explains Havelka. This creates “tremendous equity” among patients who can afford to travel to major facilities and those that can’t.

To that end, RadOnc-AI was recently awarded a $1.55 million grant from the Cancer Prevention and Research Institute of Texas, or CPRIT, a state agency that funds cancer research. The Radiological Society of North America announced late last year that InformAI was named an Aunt Minnie Best of Radiology Finalist.

“It’s quite prestigious for our company,” says Havelka. Other recent laurels include InformAI being named one of the 10 most promising companies by the Texas Life Science Forum in November.

And InformAI is only gaining steam. A third product is earlier in its stage of development. TransplantAI will optimize donor organ and patient recipient matches.

“A lot of organs are harvested and discarded,” Havelka says.

His AI product has been trained on a million donor transplants to help determine who is the best recipient for an organ. It even takes urgency into account, based on a patient’s expected mortality within 90 days. The product is currently a fully functional prototype and will soon move through its initial regulatory clearances.

The company — currently backed by three VC funds, including DEFTA Partners, Delight Ventures, and Joyance Partners — is planning to do another seed round in Q2 of 2023.

“We’ve been able to get recognized for digital health products that can be taken to market globally,” says Havelka.

But what he says he’s most excited about is the social impact of his products. With more money raised, InformAI will be able to speed up development of additional products, including expanding the cancers that the company will be targeting. And with that, more and more patients will one day be treated with the highest level of care.

Ad Placement 300x100
Ad Placement 300x600

CultureMap Emails are Awesome

Property Showcase

Houston startup lands $10M to power up electrician staffing platform

money moves

Houston-based Buildforce, which provides a tech-enabled staff platform geared toward electricians and electrical contractors, has raised a $10 million Series A round led by Houston’s Saepio Capital.

Other investors in the round include Blue Heron Capital, Revolution’s Rise of the Rest Seed Fund, S3 Ventures and Chicago Ventures.

Buildforce says the funding will help fuel its national expansion and further development of its technology.

The startup, founded in 2019, connects electricians with electrical contractors for commercial and industrial construction projects. Buildforce’s mobile app helps electricians find and carry out work, and a web app helps electrical contractors find and manage electricians.

“This financing is a major milestone in furthering our mission to help people dedicated to a career in the construction trades lead more secure and fulfilling lives,” co-founder and CEO Moody Heard said in a news release.

Buildforce focuses solely on the electrical trade within the construction sector.

Nick Graziano, principal at Blue Heron, says the shortage of electricians is intensifying as demand for electricians accelerates, driven by data center construction, infrastructure development and energy transition initiatives.

The U.S. Bureau of Labor Statistics estimates the U.S. will need to hire about 80,000 new electricians per year through 2032 to catch up with demand. According to the National Electrical Contractors Association, the U.S. is grappling with a current shortage of 50,000 electricians.

A 2026 economic report from asset manager BlackRock says the electrical trade is expected to be the single fastest-growing employment category in the U.S. labor market over the next 10 years.

“Buildforce is capitalizing on a clear opportunity in America’s generational infrastructure buildout. We believe their mission to use technology to improve lives in the construction space will allow them to make a positive long-term impact on a large and important labor market,” added Jaan Bains, managing partner at Saepio Capital.

2 Houston companies tapped to build robots for Mars & more innovation news

Trending News

Editor's note: The biggest innovation headlines in July include robots for Mars, the launch of the Texas Stock Exchange, and cancer research funding. Below are the five most-read InnovationMap articles published July 15-31, 2026:

1. Houston space companies win NASA funding to build Mars exploration robots

Two Houston-area spacetech companies have landed a portion of a $17 million award from NASA to develop robots for exploring the surface of Mars, the agency announced. Houston-based Intuitive Machines and Webster, Texas-based MEI Technologies, which does business as Aegis Aerospace, were among the seven companies selected to receive the funding from NASA's Science Transport and Robotic Innovation for Deployment and Exploration (STRIDE) initiative. Continue reading.

2. New Texas Stock Exchange officially begins trading in Dallas

Two-step aside, New York Stock Exchange and Nasdaq. The Dallas-based Texas Stock Exchange, nicknamed Y’all Street, has kicked off live trading with five stocks — and lots of Lone Star ambition. “The Texas Stock Exchange aims to revitalize competition for [stock] issuers, establish the premier venue for listings, and create a world-class trading platform for all market participants,” the exchange says. The exchange — whose Texas-influenced nickname is a nod to New York City’s Wall Street — has collected at least $275 million in investments. Continue reading.

3. Rice, Houston Methodist award $90K for cancer research projects

Rice University’s Synthesis X Center, in partnership with the Houston Methodist Neal Cancer Center, announced earlier this month the organizations would award $90,000 in seed grant funding to two projects that could help fight cancer. One would ease the pain of chemotherapy, while the other could change the way the progression of leukemia is tracked. “We’re excited to be collaborating with the Neal Cancer Center to support collaborative, novel and interdisciplinary proposals to improve cancer care and outcomes,” Han Xiao, Rice professor of chemistry and the director of the SynthX Center, said. “Together, we can achieve translational excellence.” Continue reading.

4. London AI startup selects Houston for first U.S. office after $20M raise

London-based AI firm Applied Computing has announced a $20 million Series A round and a new office in Houston. The new Bayou City office is Applied Computing’s first in the United States and part of its North American expansion. The company is known for its Orbital AI platform, which is tailored for energy operations. The funding round was led by Houston-based KBR Inc., with participation from San Francisco-based Databricks Ventures. KBR’s investment was first announced in March. Continue reading.

Report: Houston ranks among 10 most affordable metros to raise a child

Raising a child is not an easy or inexpensive feat, but a new study has determined Houston parents have the 7th lowest childrearing costs in the country. SmartAsset's new report, "Cost of Raising a Child in Major U.S. Metros – 2026 Study," calculated year-over-year changes in the annual cost of raising a child (factoring in childcare, additional housing costs, food, transportation, medical costs and other necessities) in the 48 largest U.S. metro areas. Continue reading.

Venus Aerospace adds government, C-suite leaders following $91M raise​

new leaders

Fresh off its $91 million Series B, Houston-based Venus Aerospace has made several key additions and promotions to its leadership team.

The company says its expanded team will help it deploy its high-thrust rotating detonation rocket engine (RDRE), which completed its first U.S. flight test last summer.

"We flew the world's first high-thrust RDRE in just over four years on $80 million. We believe that makes it the fastest, most capital-efficient rocket engine program in history," Sassie Duggleby, co-founder and CEO of Venus Aerospace, said in a news release. "Adding this talent to our leadership team is how we bring that same discipline to the company itself, as we scale to meet the technical needs of defense and space customers who need range and speed legacy systems can't deliver."

The key hires include:

Lane Bodian, Vice President of Public Policy

Bodian previously served as the Principal Deputy Assistant Secretary of Defense for Legislative Affairs at the Pentagon.

Dan Rebnord, Director of Federal Government Relations

Rebnord most recently served as Senior Policy Advisor to a member of the Senate Armed Services Committee and previously worked in the Office of Legislative Affairs at the Department of Defense and as Staff Director for a national security subcommittee in the House of Representatives. Rebnord and Bodian will lead Venus' work with government stakeholders.

Tom Barron, Chief Operating Officer

Barron was promoted from his role as vice president of operations for Venus Aerospace. Before his time at Venus, he served as Special Assistant to the Secretary of Defense and consulted aerospace clients at McKinsey & Company. He also served as a U.S. Army Infantry and Special Forces officer.

Nick Cardwell, Chief Product Officer

Cardwell was promoted from his role as vice president of research and development. He previously held product and technology leadership roles at VC-backed tech companies in the San Francisco Bay Area and Austin.

Venus also named Cameron Taylor as its new vice president of operations, Sarah Boland Heine as its head of communications, Matt Stohr as its head of business development, and Sheila Menz as general counsel.

The company also announced a joint technology development agreement to advance the RDRE with defense giant Lockheed Martin last week. Through the partnership, Venus and Lockheed will focus on evaluating the RDRE's propulsion architecture in defense systems, specifically for precision fires applications where weapons are designed to accurately strike targets at long distances.

Lockheed Martin Ventures, the investment arm of the aerospace and defense contractor, is an investor in Venus Aerospace.

"Lockheed Martin is focused on rapidly delivering advanced capabilities that strengthen deterrence and provide decisive advantages for the warfighter," Tim Cahill, president, Lockheed Martin Missiles and Fire Control, said in a news release. "Our collaboration with Venus Aerospace allows us to evaluate a promising propulsion technology and determine how it can be integrated into future precision fires solutions. Efforts like this help accelerate innovation, reduce risk and shorten the path from emerging technology to operational capability."

Venus' RDRE is expected to enable vehicles to travel four to six times the speed of sound from a conventional runway and is about 15 percent more efficient than traditional alternatives, according to the company.

Venus says the reusable, affordable and scalable RDRE is designed with a "common propulsion architecture" that can work for multiple industries and mission types. The company has previously estimated that the hypersonic market is projected to surpass $12 billion by 2030.

View All Listings